Cue BiopharmaCUE +0.74%63 Receivables Turnover is 1.04 as of Mar. 2026. GuruFocus rates CUE with a GF Score™ of 63/100 and a GF Value™ of $62.64 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, Cue Biopharma ranks better than 80.86% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cue Biopharma's Revenue for the
three
months ended in Mar. 2026 was $5.69 Mil. Cue Biopharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was $5.45 Mil.
Hence, Cue Biopharma's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.04.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cue Biopharma Receivables Turnover Related Terms
Cue Biopharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Cue Biopharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CUE vs ALPS, AARD, KLRS: Receivables Turnover Comparison
For the Biotechnology subindustry, Cue Biopharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cue Biopharma (CUE) has a Receivables Turnover of 1.04 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cue Biopharma and its competitors. According to the industry distribution chart, Cue Biopharma ranks #161 out of 841 companies in the Biotechnology industry, placing it in the top 19.1%.
Is Cue Biopharma's Receivables Turnover too high?
Cue Biopharma's current Receivables Turnover is 1.04. The Biotechnology industry median Receivables Turnover is 5.29. Cue Biopharma's value of 1.04 is 80.3% below this industry median. Based on the distribution chart, Cue Biopharma ranks #161 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cue Biopharma has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Receivables Turnover compare to ALPS and AARD?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #161 out of 841 companies for Receivables Turnover. This places Cue Biopharma in the top 19% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. Cue Biopharma's value of 1.04 is 80.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cue Biopharma's current Receivables Turnover of 1.04 is 80.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cue Biopharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cue Biopharma's current Receivables Turnover is 1.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.64, compared to a current price of $36.78 — trading 41.3% below its estimated fair value. The current Receivables Turnover is 1.04 and 80.3% below the Biotechnology industry median of 5.29. Cue Biopharma's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Receivables Turnover is 1.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cue Biopharma (CUE) Overvalued in 2026?
Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued.
The current stock price of $36.78 is trading 41.3% below its estimated GF Value™ of $62.64.
GuruFocus considers Cue Biopharma to be Possible Value Trap.
Key valuation signals for CUE:
Receivables Turnover: 1.04
GF Value™: $62.64 vs. price of $36.78 (41.3% below fair value)
Industry Position: 80.3% below the Biotechnology median (#161 of 841)
No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
63GF Score
Get the complete analysis for CUE
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUE has been successfully added to your 
